KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1611-1624

  Moran, Diarmuid M ^a   Trusk, Patricia B ^a   Pry, Karen ^a   Paz, Keren ^d   Sidransky, David ^c,d,e   Bacus, Sarah S ^a,b  

^a IQVIA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Champions Oncology   (United States)

^e Champions Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; PEMETREXED; FOLIC ACID; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FOLATE METABOLISM; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PURINE SYNTHESIS; ANIMAL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NADP); MICE; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902657533     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0649     Document Type: Article

References (42)

1. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007;26:153-81. (Pubitemid 46452189)
2. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002;1587:164-73. (Pubitemid 34657277)
3. Vazquez A, Tedeschi PM, Bertino JR. Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. Cancer Res 2013;73:478-82.
4. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
5. Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep 2003;5:114-25. (Pubitemid 38898774)
6. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C. Pemetrexed in the treatment of advanced nonsquamous lung cancer. Lung Cancer 2009;66:141-9.
7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer. J Clin Oncol 2008;26:3543-51.
8. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308. (Pubitemid 46480970)
9. Pao W, Girard N. New driver mutations in non -small cell lung cancer. Lancet Oncol 2011;12:175-80.
10. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5.
11. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
12. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2007;13:2890 -6.
13. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000;19:6584-93. (Pubitemid 32197696)
14. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22. (Pubitemid 37328883)
15. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identi fies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
16. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137:821-34.
17. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
18. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010;18:63-73.
19. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011;7:523.
20. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012;149:656-70.
21. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325:1555-9.
22. Schernhammer ES, Giovannuccci E, Fuchs CS, Ogino S. A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status. Cancer Epidemiol Biomarkers Prev 2008;17:2895-8.
23. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6:820-32. (Pubitemid 46554552)
24. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. Cell Miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res;72:3499-511.
25. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23. (Pubitemid 44450469)
26. Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005;3:413-23. (Pubitemid 41045591)
27. Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther 2011;10:336-46.
28. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-64. (Pubitemid 27232866)
29. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010;107:8788-93.
30. Kappock TJ, Ealick SE, Stubbe J. Modular evolution of the purine biosynthetic pathway. Curr Opin Chem Biol 2000;4:567-72.
31. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455:679-83.
32. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105:18782-7.
33. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 2005;65:8433-41. (Pubitemid 41330610)
34. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res 2006;66:10843-8. (Pubitemid 44876980)
35. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10:1311-6.
36. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 2012;10:125.
37. Wang T, Chuan Pan C, Rui Yu J, Long Y, Hong Cai X, De Yin X, et al. Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis. PLoS ONE 2013;8:e74284.
38. Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 2013;8:930-9.
39. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011;104:1594-601.
40. Levy B, Seetharamu N, Richardson S, Becker DJ, Choi W, Evans A, et al. KRAS mutations and outcomes for patients with stage IV NSCLC treated with frontline platinum/pemetrexed based chemotherapy. ASCO Meet Abstr 30, 2012. (suppl; abstr e18139)
41. Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011;6:774-80.
42. Scagliotti GV, Ceppi P, Capelletto E, Novello S. Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer 2009;10 Suppl 1:S35-40.